Junshi’s Phase III PD-1 blocker shows promise in NSCLCR&D, TherapeuticsJunshi Biosciences’ Neotorch is the world’s first registered Phase III immuno-oncology trial for lung cancer to post positive EFS (event-free survival) data. Read more January 18, 2023/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/09/BioSpacelungcancer9-13-2022.jpg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2023-01-18 09:38:412023-01-18 09:39:36Junshi’s Phase III PD-1 blocker shows promise in NSCLC
